Australia's Imugene jumps on ethics approval to study cancer treatment

Imugene

23/03/2022 01:01

** Shares of Imugene  IMU.AX  climb as much as 9.6% to
A$0.285, set for their best session since March 17 if gains hold
    ** The cancer-focused biopharma co receives https://www.asx.com.au/asxpdf/20220323/pdf/4578jxzgm3rnj9.pdf
 Western Institutional Review Board approval to commence a Phase
I clinical trial of its oncolytic virotherapy candidate, VAXINIA
    ** Says the Phase I trial will study multiple solid tumours
in patients
    ** Adds the trial is anticipated to run for 24 months 
    ** Stock down ~35% so far this year, as of last close 

 (Reporting by Upasana Singh in Bengaluru)
 ((Upasana.Singh@thomsonreuters.com))